554 related articles for article (PubMed ID: 35361691)
1. Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
Sidler D; Born A; Schietzel S; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Seyed Jafari SM; Radonjic-Hoesli S; Chan A; Hoepner R; Bacher U; Mani LY; Iype JM; Suter-Riniker F; Staehelin C; Nagler M; Hirzel C; Maurer B; Moor MB
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35361691
[TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
[TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
4. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
[TBL] [Abstract][Full Text] [Related]
5. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
6. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases.
Sieiro Santos C; Calleja Antolin S; Moriano Morales C; Garcia Herrero J; Diez Alvarez E; Ramos Ortega F; Ruiz de Morales JG
RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987093
[TBL] [Abstract][Full Text] [Related]
8. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
9. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
Front Immunol; 2022; 13():960001. PubMed ID: 36311767
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
Front Immunol; 2022; 13():892277. PubMed ID: 35669765
[TBL] [Abstract][Full Text] [Related]
13. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
14. Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.
Rizzo R; Bortolotti D; Morandi L; Rizzo S; Schiuma G; Beltrami S; Papi A; Contoli M
Int J Infect Dis; 2022 Sep; 122():412-414. PubMed ID: 35750264
[TBL] [Abstract][Full Text] [Related]
15. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
16. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.
Shirata M; Ito I; Tanaka M; Murata K; Murakami K; Ikeda H; Oi I; Hamao N; Nishioka K; Hayashi Y; Nagao M; Hashimoto M; Ito H; Ueno H; Morinobu A; Hirai T
Clin Exp Med; 2023 Dec; 23(8):4707-4720. PubMed ID: 37582911
[TBL] [Abstract][Full Text] [Related]
17. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
18. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
[TBL] [Abstract][Full Text] [Related]
19. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
